Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 30.00 | |
2 mg | In stock | $ 43.00 | |
5 mg | In stock | $ 68.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 188.00 | |
50 mg | In stock | Inquiry | |
1 mL * 10 mM (in DMSO) | In stock | $ 81.00 |
Description | Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. |
In vitro | Administration of 6-60?μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis[1]. |
In vivo | Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells[2]. |
Molecular Weight | 313.4 |
Formula | C17H23N5O |
CAS No. | 1020412-43-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 18 mg/mL (57.43 mM)
DMF: 18 mg/mL (57.43 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Gardiquimod 1020412-43-4 Immunology/Inflammation Microbiology/Virology Proteases/Proteasome HIV Protease TLR HIV-1 HepG2 Toll-like Receptor (TLR) Inhibitor PBMCs inhibit HIV cells peripheral macrophages blood liver carcinoma Human immunodeficiency virus mononuclear inhibitor